OncoMatch/Clinical Trials/NCT06592924
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Is NCT06592924 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for prostate cancer (adenocarcinoma).
Treatment: Abiraterone · Enzalutamide · Apalutamide · Darolutamide (BAY 1841788) · Docetaxel · ADT — This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better or worse than the usual approach for prostate cancer. The usual approach for patients who are not in a study is hormone treatment with Androgen Deprivation Therapy (ADT) and Androgen-Receptor Pathway Inhibitor (ARPI).
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: androgen deprivation therapy — for mCSPC for at least 6 months and no greater than 12 months at time of enrollment
Receipt of ADT for mCSPC for at least 6 months and no greater than 12 months at time of enrollment.
Must have received: androgen receptor pathway inhibitor (abiraterone acetate, enzalutamide, apalutamide, darolutamide) — for at least 4 months at time of enrollment
Receipt of ARPI (e.g. abiraterone acetate, enzalutamide, apalutamide, or darolutamide) for at least 4 months at time of enrollment
Cannot have received: taxane
Prior treatment with taxane chemotherapy
Lab requirements
Blood counts
Adequate organ and marrow function measured within 14 days prior to enrollment.
Kidney function
Adequate organ and marrow function measured within 14 days prior to enrollment.
Liver function
Adequate organ and marrow function measured within 14 days prior to enrollment.
Cardiac function
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class II or better.
Adequate organ and marrow function measured within 14 days prior to enrollment. Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class II or better.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Anchorage Associates in Radiation Medicine · Anchorage, Alaska
- Alaska Breast Care and Surgery LLC · Anchorage, Alaska
- Alaska Oncology and Hematology LLC · Anchorage, Alaska
- Alaska Women's Cancer Care · Anchorage, Alaska
- Katmai Oncology Group · Anchorage, Alaska
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify